18F-FDG PET/CT影像组学预测晚期NSCLC免疫检查点抑制剂治疗的临床获益
本研究纳入194例IIIB-IV期NSCLC患者,基于治疗前18F-FDG PET/CT提取影像组学特征,构建多参数影像组学标签(mpRS)预测持久临床获益(DCB)。mpRS在训练集、回顾性测试集和前赡性测试集的AUC分别为0.86、0.83和0.81,列线图模型预测PFS和OS的C-index分别为0.74-0.77和0.80-0.83。PET/CT影像组学标签可在免疫治疗前识别最可能获益的NSCLC患者。
要点
- 基于治疗前PET/CT的mpRS可预测NSCLC患者免疫治疗DCB,三队列AUC为0.86、0.83、0.81。
- 结合临床特征的列线图预测PFS的C-index为0.74-0.77,预测OS的C-index为0.80-0.83。
- 影像组学标签有望在免疫治疗前辅助个体化决策。
核心结论
- 基于PET/CT的影像组学标签可在免疫治疗开始前识别最可能从免疫检查点抑制剂治疗中获益的晚期NSCLC患者。
研究设计与样本
- 本研究纳入194例经组织学确诊的IIIB-IV期NSCLC患者,均有治疗前PET/CT图像。
- 从PET、CT和PET+CT融合图像中基于最小Kullback-Leibler散度(KLD)准则提取影像组学特征。
- 利用99例回顾性患者以改进的最小绝对收缩和选择算子(LASSO)方法训练多参数影像组学标签(mpRS)预测DCB,并在回顾性测试队列(N=47)和前赡性测试队列(N=48)中验证。
- 使用多变量Cox回归分析纳入额外临床特征训练列线图模型,预测PFS和OS。
主要发现
- mpRS预测DCB的AUC在训练集、回顾性测试集和前赡性测试集分别为0.86(95%CI 0.79-0.94)、0.83(95%CI 0.71-0.94)和0.81(95%CI 0.68-0.92)。
- 列线图模型预测PFS的C-index在训练集、回顾性测试集和前赡性测试集分别为0.74(95%CI 0.68-0.80)、0.74(95%CI 0.66-0.82)和0.77(95%CI 0.69-0.84)。
- 列线图模型预测OS的C-index在训练集、回顾性测试集和前赡性测试集分别为0.83(95%CI 0.77-0.88)、0.83(95%CI 0.71-0.94)和0.80(95%CI 0.69-0.91)。
临床怎么用
- 对于拟接受免疫检查点抑制剂治疗的晚期NSCLC患者,可利用治疗前18F-FDG PET/CT影像组学标签辅助预测DCB,支持更精准的个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunotherapy has improved outcomes for patients with non-small cell lung cancer (NSCLC), yet durable clinical benefit (DCB) is experienced in only a fraction of patients. Here, we test the hypothesis that radiomics features from baseline pretreatment 18F-FDG PET/CT scans can predict clinical outcomes of NSCLC patients treated with checkpoint blockade immunotherapy. METHODS: This study included 194 patients with histologically confirmed stage IIIB-IV NSCLC with pretreatment PET/CT images. Radiomics features were extracted from PET, CT, and PET+CT fusion images based on minimum Kullback-Leibler divergence (KLD) criteria. The radiomics features from 99 retrospective patients were used to train a multiparametric radiomics signature (mpRS) to predict DCB using an improved least absolute shrinkage and selection operator (LASSO) method, which was subsequently validated in both retrospective (N = 47) and prospective test cohorts (N = 48). Using these cohorts, the mpRS was also used to predict progression-free survival (PFS) and overall survival (OS) by training nomogram models using multivariable Cox regression analyses with additional clinical characteristics incorporated. RESULTS: The mpRS could predict patients who will receive DCB, with areas under receiver operating characteristic curves (AUCs) of 0.86 (95%CI 0.79-0.94), 0.83 (95%CI 0.71-0.94), and 0.81 (95%CI 0.68-0.92) in the training, retrospective test, and prospective test cohorts, respectively. In the same three cohorts, respectively, nomogram models achieved C-indices of 0.74 (95%CI 0.68-0.80), 0.74 (95%CI 0.66-0.82), and 0.77 (95%CI 0.69-0.84) to predict PFS and C-indices of 0.83 (95%CI 0.77-0.88), 0.83 (95%CI 0.71-0.94), and 0.80 (95%CI 0.69-0.91) to predict OS. CONCLUSION: PET/CT-based signature can be used prior to initiation of immunotherapy to identify NSCLC patients most likely to benefit from immunotherapy. As such, these data may be leveraged to improve more precise and individualized decision support in the treatment of patients with advanced NSCLC.
引用
- Mu W, Tunali I, Gray JE, et al. Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging. 2019. PMID: 31807885. doi:10.1007/s00259-019-04625-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。